New Paediatric Resident Handbook!
The Canadian Association of Paediatric Nephrology is excited to announce the release of a new Resident Handbook for Paediatric Nephrology Trainees!
Join us in Calgary, Alberta for the 19th IPNA Congress
The Canadian Association of Paediatric Nephrologists (CAPN), representing the 14 centers in Canada, invites you to visit Calgary in September 2022 to attend the 19th Congress of the International Pediatric Nephrology Association. Our team at the Alberta Children’s Hospital (University of Calgary) has provided full pediatric nephrology care for 25 years; our researchers have taken a leadership role in the pan-Canadian study of Nephrotic Syndrome. We are delighted to have this opportunity to meet colleagues from around the world and focus on how to improve the health of children and young adults with kidney disease. The 2022 IPNA Congress program will include clinical and scientific presentations as well as interactive workshops and we look forward to sharing more details with you as we develop the program.
The Congress will take place at the TELUS Convention Centre located in downtown Calgary within easy walking distance of the host hotels and local attractions. Take a stroll along the pedestrian friendly Stephen Avenue for some shopping, visit one of the many restaurants or walk a short distance to the pathways along the Bow River, a world-renowned destination for fly fishing adventures. Calgary is a safe, clean and accessible city with an exciting culinary scene. We are located next door to the Canadian Rocky Mountains the Canadian Badlands and five UNESCO World Heritage Sites. Bucket list destinations like Banff and Lake Louise are only an hour away. Find out more about Calgary and the surrounding area. We encourage you to take a few days before or after the IPNA 2022 Congress to enjoy everything Calgary and Alberta have to offer. We are very excited to host and welcome you to our vibrant city and look forward to seeing you in Calgary in 2022!
A statement from the Canadian Association of Paediatric Nephrologists on recent issues of racism.
Along with many of you, we have watched the events of the past week unfold in the United States, events which are compounding an already challenging time. We want to acknowledge firmly and explicitly that while the issue of anti-Black racism is at the forefront in the US, we cannot ignore that this reality exists here in Canada, and right in our own community.
Violence and discrimination against Black, Indigenous, and racialized peoples is embedded in all aspects of our Canadian society which unfortunately includes the health-care system. We have work to do. CAPN values and is strengthened by the diversity in our community and we are well suited to serve as a role model.
Addressing the issue of racial inequality is on all of us. It is our collective accountability not just to identify as anti-racist, but to do the work. Demonstrating through our words, actions, and behaviours, that we will not tolerate acts of racism in our community is the only way to effect positive, meaningful change. Please take a moment to think about your own position, what privilege you may have, and ways that you can make a difference. We are hopeful that together as a community, this issue will continue to be acknowledged as change will not happen alone..
Join us in acknowledging George Floyd, one of the many victims whose lives have been lost or irrevocably altered by systemic racism. We are deeply saddened that it has taken the death of yet another human life to move our collective conversation to a level that we hope may bring us closer to a more peaceful, equitable society.
"Improving paediatric medications: A prescription for Canadian children and youth" white paper released in collaboration with Canadian Pediatric Society and Rosalind and Morris Goodman Family Pediatric Formulations Centre
The Canadian Pediatric Society and Goodman Family Centre Pediatric Formulation Centre, in collaboration with many pediatric stakeholders, including the Canadian Association of Pediatric Nephrology, released a white paper on pediatric medication equity, published in the Journal of Pediatrics and Child Health. The paper outlines an approach to creating equity in access to medications in Canada for pediatric patients, including recommendations for future regulatory systems and research focus.
Update for Canadian Cystinosis Patients
CAPN has recently been informed that Cystagon will undergo a Health Canada review for approval in Canada, making the drug available to Canadian cystinosis patients through regular prescription. The manufacturer has stated that the market price of Cystagon will be no higher than 1/3 of the cost of Procysbi. We will post updates on the progress of the application as it comes available.
Ongoing advocacy efforts regarding Procysbi and special access restrictions for Cystagon
Many patients and pediatric nephrologists were concerned to hear access to Cystagon through the Health Canada Special Access Program was restricted earlier this year with the approval of Procysbi for marketing in Canada for treatment of infantile nephropathic cystinosis. Procysbi underwent a common drug review through the Canadian Agency for Drugs and Technologies in Health (CADTH), which recommended funding Procysbi through the Provincial Drug Monitoring Boards, if there was a "significant cost reduction" in the proposed market price. To date, no province has confirmed that they will fund the higher cost of Procysbi. Several efforts have been ongoing to address this specific issue of access to medication:
1. CAPN has posted a letter to Health Canada detailing our concerns regarding the ability to lock out a less expensive therapy that is meeting the needs of many patients with nephropathic cystinosis. Since that time, the Health Canada Special Access Program (SAP) program has been very helpful in assisting clinicians throughout the country transition our patients with nephropathic cystinosis to Procysbi. Physicians should be aware that Cystagon is still available through SAP for patients who meet the following criteria:
- G-tube fed with small tubes
- Receiving sodium bicarbonate
Patients who do not meet these criteria cannot access Cystagon through SAP because Health Canada has strict regulations which they must abide for fair market competition.
2. Cystagon has never gone through the approval process in Canada. It is important for physicians to know that if we are prescribing a non-Health Canada approved medication i.e: Cystagon, we are liable if there was ever a medical error in the fabrication of the medication.
We encourage clinicians to contact the Health Canada SAP program if they want their patients to be eligible for Cystagon. To our knowledge, no patient has been left without treatment.
CAPN recently was contacted by the new distributor of Cystagon regarding marketing of Cystagon in Canada. Cystagon has been sold to a company who is already working in rare diseases in Canada and there is a will to have Cystagon approved by Health Canada. Approval of Cystagon for marketing in Canada will allow families and physicians to decide which medication is best to control their disease. However, it does not guaranty that the cost of Cystagon will remain lower than Procysbi. We will keep you updated on the situation but it may take time.
In addition, Pediatric Nephrologist Dr. Julian Midgley from Alberta Children's Hospital was featured on a March 10, 2018 online CBC article advocating on this issue and its impact on patient well-being.
CAPN has also joined a consortium of organizations concerned about formulary fairness for children in Canada, led by the Goodman Centre for Pediatric Formulations and the Canadian Paediatric Society. Together, we aim to bring issues affecting equity and access to pediatric medications in Canada to the forefront.
CAPN strongly supports that all patients with infantile cystinosis receive coverage for cystine-depleting agents by all provinces and territories. This is life sustaining therapy. All efforts should be made that the medication is competitively priced and that choices exist that allow concomitant bicarbonate therapy in pre-transplant patients.
The Canadian Childhood Nephrotic Syndrome Project
CHILDNEPH recruitment centres across Canada